Navana Pharmaceuticals PLC

NAVANAPHAR

BD0497NAVPH5

Pharmaceuticals

End-of-day quote Dhaka S.E. Other stock markets 23:00:00 10/06/2024 BST			5-day change	1st Jan Change
88.2 ^BDT	+2.56%		-2.86%	+4.50%

05-13	Navana Pharmaceuticals PLC Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	CI
02-07	Navana Pharmaceuticals PLC Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	CI

Navana Pharmaceuticals Limited Recommends Cash Dividend for the Year Ended June 30, 2023

October 23, 2023 at 04:04 pm

The board of directors of Navana Pharmaceuticals Limited has recommended 13% cash dividend for the year ended June 30, 2023.

Latest news about Navana Pharmaceuticals PLC

Navana Pharmaceuticals PLC Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	05-13	CI
Navana Pharmaceuticals PLC Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	02-07	CI
Navana Pharmaceuticals Limited will Change its Name to Navana Pharmaceuticals PLC	01-28	CI
Navana Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended September 30, 2023	11-22	CI
Navana Pharmaceuticals Limited Recommends Cash Dividend for the Year Ended June 30, 2023	23/10/23	CI
Navana Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	15/05/23	CI
Navana Pharmaceuticals Limited Recommends Dividend for the Year Ended June 30, 2022	30/10/22	CI
Navana Pharmaceuticals Limited has completed an IPO in the amount of BDT 750.000016 million.	18/10/22	CI
Navana Pharmaceuticals Limited has filed an IPO in the amount of BDT 750 million.	15/12/21	CI

Chart Navana Pharmaceuticals PLC

Duration

Period

More charts

Navana Pharmaceuticals Limited is a Bangladesh-based pharmaceutical company. The Company is engaged in manufacturing, marketing, and distribution of pharmaceutical products for human and animal health products and sales of the produced items in the domestic and foreign market. The Company is engaged in manufacturing, marketing and distribution of generic pharmaceuticals finished products, which includes human drugs dosages form like tablet, capsule, powder for suspension, cream, ointment, powder, injection, eye and nasal drop, liquid, sachet products, oral solution, veterinary drugs dosages form like vaccine, bolus, liquid, injection, water soluble powder and premix. Its products include Alleloc DS, Duracef, Nafgal, L-Amlo, Navix, Nestor, Tabis, Tabis plus, Imigra, Pizofen, Pregan, Dextac Capsule, Joytrip Chewable Tablet, Prulicon Tablet, Toma, Odafen, Desatrol, Arokast, Bonacerin, Azirox, Esona, Clonipres, Meltix, Diplin, among others.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NAVANA PHARMACEUTICALS PLC	+4.50%	78.59M
ELI LILLY AND COMPANY	+48.53%	779B
NOVO NORDISK A/S	+40.67%	631B
JOHNSON & JOHNSON	-6.37%	354B
MERCK & CO., INC.	+20.93%	333B
ABBVIE INC.	+8.21%	301B
ASTRAZENECA PLC	+16.75%	249B
ROCHE HOLDING AG	-1.19%	216B
NOVARTIS AG	+10.85%	214B
AMGEN INC.	+4.40%	163B

Other Pharmaceuticals

Navana Pharmaceuticals PLC

Equities

NAVANAPHAR

BD0497NAVPH5

Pharmaceuticals

Navana Pharmaceuticals Limited Recommends Cash Dividend for the Year Ended June 30, 2023

Latest news about Navana Pharmaceuticals PLC

Chart Navana Pharmaceuticals PLC

Company Profile

Income Statement Evolution

Sector Other Pharmaceuticals